Accelmed

Accelmed sits in a corner of healthcare investing that most venture firms quietly avoid: commercial-stage HealthTech that is too capital-intensive for traditional venture and too operationally complex for generalist private equity. The firm, with offices serving the United States and Israel and roughly $630 million in assets under management, specializes in growth and buyout investments in companies that already have product, customers, and revenue but need a different kind of partner to reach scale. For founders of medical device, diagnostics, and digital health companies that have crossed the commercial threshold and now face the harder problem of building a durable business, Accelmed is one of a small number of firms purpose-built for the moment.

The thesis is that commercial-stage HealthTech needs operationally engaged capital rather than additional venture growth equity. Within medical devices and MedTech, diagnostics, digital health, and care delivery and tech-enabled services, Accelmed targets companies with established commercial traction and clear unit economics, and they bring a private equity playbook to professionalize operations, expand commercial reach, and build out leadership teams. The firm is comfortable with both minority growth investments and majority buyouts, and they will frequently participate in carve-outs and recapitalizations alongside traditional growth equity. Founders should expect a partner whose first questions are about gross margin, sales productivity, and customer cohorts rather than about narrative and TAM. Accelmed is not the right partner for a pre-revenue technical bet; they are the right partner for a company that has demonstrated commercial product-market fit and now needs operating help to compound.

Accelmed’s portfolio reflects the commercial-stage focus, with investments in medical device and diagnostics companies serving hospital systems, ambulatory surgery centers, and specialty providers, alongside digital health companies with established revenue. The pattern is companies with proven products, defensible regulatory positions, and a path to either strategic acquisition or a larger growth round. The firm’s cross-border presence in the United States and Israel is meaningful: Accelmed has historically been one of the more reliable growth partners for Israeli HealthTech companies looking to scale commercial operations in the US market, and the firm’s operating network reflects that geography.

Check sizes are $25 million and up, consistent with the firm’s positioning at Series B, Series C, and growth stages. Accelmed will write growth checks into priced rounds, lead recapitalizations, and execute majority buyouts in the right circumstances. The capital stack positioning is that of a commercial-stage specialist who can either anchor a growth round or take control of a company through a buyout, and the firm’s flexibility on transaction structure is one of its more useful features for founders navigating complex cap tables. Reserves are sized for follow-on participation through exit, and the firm is comfortable holding companies for longer than the typical venture window when the operating thesis requires it.

The firm is led by senior investors with backgrounds in HealthTech operating, private equity, and cross-border transactions between the United States and Israel. Decision-making is investment-committee-driven, with diligence processes that resemble private equity more than venture: detailed commercial diligence, full-quality-of-earnings work, and operating-team interviews. Founders should expect a slower process than a typical Series B but a more substantive operating partnership at the end of it. The firm’s communication style is direct and operationally focused.

The most reliable path into Accelmed is a warm introduction from a portfolio CEO, a HealthTech investment banker who has transacted with the firm, or a senior operator in the medical device and diagnostics ecosystem. Cross-border introductions through Israel-focused investment banks and HealthTech advisors are particularly effective. Cold outreach from credible commercial-stage companies is read and converted more often than at typical venture firms, in part because the firm’s deal flow at growth stage is sourced from a smaller universe.

Approach Accelmed when you are running a commercial-stage HealthTech company that needs operating help and growth capital, when you are open to a private-equity-style partnership that includes operational transformation, or when you are evaluating a recapitalization or carve-out. Do not approach when you are pre-revenue, when you are running a traditional venture process for a Series A, or when you want a passive growth check without operating engagement. Accelmed is a specialized, hands-on growth partner for HealthTech companies that have crossed the commercial threshold and need a different kind of investor to compound from there.